Efficacy and tolerability of levetiracetam in patients with therapy-resistant epilepsy and learning disabilities

Seizure

Volumn 13, Issue 3, 2004, Pages 168-175

  Huber, Bernd ^a   Bommel W ^a   Hauser, I ^a   Horstmann, V ^a   Liem, S ^a   May, Th ^a   Meinert, T ^a   Robertson, E ^a   Schulz, L ^a   Seidel, M ^a   Tomka Hoffmeister, M ^a   Wagner, W ^a  

^a EPILEPSY CENTER BETHEL   (Germany)

Author keywords

Antiepileptic drugs; Epilepsy; Learning disability; Levetiracetam

Indexed keywords

CARBAMAZEPINE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; MESUXIMIDE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; VALPROIC ACID;

ADOLESCENT; ADULT; AGED; ALERTNESS; ANOREXIA; ANTICONVULSANT ACTIVITY; APATHY; ARTICLE; ATAXIA; CONSCIOUSNESS DISORDER; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPSY; FEMALE; FOCAL EPILEPSY; FREQUENCY ANALYSIS; GAIT DISORDER; GENERALIZED EPILEPSY; HALLUCINATION; HEALTH CENTER; HEALTH STATUS; HUMAN; LEARNING DISORDER; LENNOX GASTAUT SYNDROME; MALE; MEDICAL DECISION MAKING; MEDICAL RECORD; MENTAL DISEASE; MENTAL HEALTH; MOOD; PARANOID PSYCHOSIS; PRIORITY JOURNAL; RATING SCALE; SEIZURE; SIDE EFFECT; SOMNOLENCE; TREMOR; VOMITING;

EID: 12144287263     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1059-1311(03)00154-7     Document Type: Article

References (11)

1. Shorvon, S. D. et al. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group. Epilepsia 2000; 41 (9): 1179-1186.
2. Ben-Menachem, E. and Falter, U. Efficacy and tolerability of levetiracetam 3000 mg/day in patients with refractory partial seizures: A multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. Epilepsia 2000; 41 (10): 1276-1283.
3. Cereghino, J. J. et al. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000; 55 (2): 236-242.
4. Privitera, M. Efficacy of levetiracetam: A review of three pivotal clinical trials. Epilepsia 2001; 42 (Suppl. 4): 31-35.
5. Betts, T., Waegemans, T. and Crawford, P. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure 2000; 9 (2): 80-87.
6. Gibson, G. Efficacy of levetiracetam in developmentally disabled patients: A review of the literature and six case reports. Epilepsy & Behavior 2002; 3: 280-284.
7. Linden, M. et al. Leitlinien zur Durchführung von Anwendungsbeobachtungen in der Psychopharmakatherapie. Der Nervenarzt 1994; 65: 638-644.
8. Huber, B., May, T. and Seidel, M. Lamotrigine in multihandicapped therapy-resistant epileptic patients. Clinical Drug Investigation 1998; 16 (4): 263-277.
9. Huber, B. and Tomka-Hoffmeister, M. Limited efficacy of gabapentin in severe therapy-resistant epilepsies of learning disabled patients. Seizure (in press).
10. Huber, B. Effects of topiramate in patients with epilepsy and intellectual deficits. Nervenarzt 2002; 73: 525-532.
11. Engel, J. Jr A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: Report of the ILAE Task Force on Classification and Terminology. Epilepsia 2001; 42 (6): 796-803.